PPH Legal Blog

Arena Pharmaceuticals is convinced that they can create a weight-loss drug from the same family of drugs as the notorious fen-phen without causing heart valve damage or primary pulmonary hypertension.
A safety review of the drug which involved a 12 month trial shows no heart valve damage or hypertension in patients who participated in the study. […]

[Read more →]

Due to the fall-out from Avandia and other diabetes drugs, the FDA is considering stricter rules for testing the effects of diabetes drugs on the human heart prior to sale.
Drug safety advocates are praising the move while investors aren’t too keen on the idea. All of the concerns follow reports that Avandia increases an individual’s […]

[Read more →]

A 2007 law that requires all clinical studies of new medications, except Phase-1 Safety Studies, is increasing the amount of information available to patients and doctors alike.
This new law is particularly useful because pharmaceutical companies frequently don’t disclose any negative results of their clinical trials. In addition, they don’t publish results that show very little […]

[Read more →]

The FDA’s recently criticized review and approval process is under investigation by the Government Accountability Office. The GAO is investigating reports that the review process allowed 2 blockbuster drugs through without sufficient proof of their effectiveness or lack of harmful side effects.
Sen. Charles Grassley, an Iowa Republican, requested the investigation after studies have shown that […]

[Read more →]

There has been a rise in hospitalizations for PPH in recent months. This can be seen as either a good thing or a bad thing. It is bad because it means that there are more people needing hospital stays to help with their disease. The good news is that doctors are catching the disease and […]

[Read more →]